BioControl starts clinical study

CardioFit is an electrical stimulator system designed to improve heart function through the controlled stimulation of the vagus nerve.

By AVI KRAWITZ
January 11, 2007 07:20

Yehud-based biotechnology start-up BioControl Medical said Wednesday it was enrolling patients for an international, multi-center, open-label study of its CardioFit system for the treatment of congestive heart failure system at sites in Europe, Israel and Australia. CardioFit is an electrical stimulator system designed to improve heart function through the controlled stimulation of the vagus nerve. Early data show that the CardioFit system is safe to implant in patients with NYHA class III heart failure, the company said.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 10 - 21
    Beer Sheva
    11 - 20
    Tel Aviv - Yafo
  • 9 - 16
    Jerusalem
    10 - 18
    Haifa
  • 15 - 25
    Elat
    12 - 22
    Tiberias